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Crises like the COVID-19 pandemic affect firms’ innovation management and decision 
making. On the downside, crises lead to detriments like budget constraints, to which firms 
often respond by reducing their innovation activities. On the upside, crises are opportuni-
ties, where some firms exploiting changing market requirements and necessities excel. No 
matter in which direction, decision makers must react quickly but often rely on ad-hoc 
decisions or even gut feeling when drafting their crisis response strategies. Through a series 
of distinct cases, we demonstrate that innovation management may fill this void through 
patent analytics. Drawing on biochemical expertise, we particularly describe the functions 
and effects of COVID-19. To counter downside detriments, firms may circumvent budget 
constraints by discerning patents that can be (1) monetized, for example via sales or licens-
ing deals, or (2) abandoned to achieve cost-savings, allowing firms to maintain their inno-
vation activities. To realize upside opportunities, firms and governments may use patent 
analytics to detect key biotechnology firms that are likely to successfully develop treatments 
and vaccinations against pandemics like COVID-19. Promulgated U.S. interest in relocating 
foreign firms to the United States is not without technological and commercial reasoning. 
Herein, the insights of this study contribute to a better understanding of the use of patent 
information, such as smart patent indicators, harmonized patent data, novel annuity fee 
measures, and hand-collected datasets of COVID-19 and related antibodies’ patents to the 
management of innovation in times of crisis.
1.  Introduction
The recent outbreak of the novel virus SARS-CoV-2 has developed into a worldwide pandemic 
from late 2019 onwards (e.g., Rothan and Byrareddy, 
2020). Firms all over the world suffer from eco-
nomic detriments due to lockdown-induced demand 
reductions, resulting in budget constraints, uncertain 
innovation prospects, and unpredictable future devel-
opments (Paunov, 2012; Tietze et al., 2020). Whilst 
most prior crises were limited to specific industrial 
sectors, countries, or firms, the COVID-19 pandemic 
is truly global, affecting everyone.
On the downside, prior research investigating 
innovation management in crises found crises to 
intensify ‘uncertainty, complexity, ambiguity and 
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unpredictability’ (Davis et al., 2009; Martin-Rios 
and Pasamar, 2018). Corporate decision makers 
have to react quickly, consider future effects, and 
simultaneously generate options to overcome the 
crisis here and now (Teece et al., 2016). These 
reactions are typically ad hoc and based on gut 
feelings instead of sufficient information (e.g., 
Müller, 1985; Cooper and Edgett, 2010; Bessant 
et al., 2015). For example, firms often cut their 
innovation investments despite negative long-term 
consequences, as visible in reduced patent filings, 
forfeiting the firms’ future (Archibugi et al., 2013b; 
Hingley and Park, 2017).
On the upside, prior research since Schumpeter’s 
(1934) seminal work simultaneously demonstrated 
that crises-induced financial constraints foster inno-
vation (Hoegl et al., 2008). For example, Archibugi 
et al. (2013a) found that whilst crises lead to con-
centrations of innovative activities for growing and 
innovative firms, expanding explorative strategies 
enable firms to better cope with and overcome cri-
ses. In addition to those firms that suffer from the 
crises, some winners emerging stronger also exist 
(Archibugi et al., 2013b). For example, firms like 
AirBnB and Uber emerged like a phoenix arising 
from the ashes after the recent financial crisis, with 
innovative offerings matching crises’ Zeitgeist and 
market requirements (e.g., Oskam and Boswijk, 
2016; Zervas et al., 2017). However, success stories 
become success stories ex-post only, not when they 
begin.
In fact, it is challenging and often a mere chance 
to successfully bet on future winners without suffi-
cient data to back decisions, and even more difficult 
though in crisis situations (e.g., Sah and Stiglitz, 
1986; Christensen and Knudsen, 2010; Denrell and 
Fang, 2010). It is surprising that only little scholarly 
attention has been paid to investigating the possi-
bilities that publicly available information offers 
for organizational decision making, not only in the 
global COVID-19 pandemic, but in crises in gen-
eral. In this paper, we address this gap by studying 
how innovation management decisions in times of 
crisis like the COVID-19 pandemic can be improved 
through publicly available data.
To address this research question, we turn to patent 
analytics (Campbell, 1983; Ashton and Sen, 1988; 
Ernst, 2003). We show how patent analytics may 
shape innovation management during crises (e.g., 
Campbell, 1983; Archibugi et al., 2013a; Guderian, 
2019). By drawing on longitudinal and cross- 
sectional patent data, we present four distinct case 
studies. The first two cases address the downside, 
i.e., how locked-down firms can reduce expenses, 
free budget to continue innovation efforts, and may 
generate excess revenue based on data-driven deci-
sions, for example by identifying technology licens-
ing and abandonment candidates. The latter two 
cases address the upside, i.e., how success stories are 
identifiable ahead of time using data on their technol-
ogies and innovation activities, for example, to detect 
the most promising candidates to develop COVID-19 
treatments and vaccinations.
The insights of this study yield several contri-
butions to the literature on innovation management 
in times of crises and patent analytics in innovation 
management (e.g., Döner, 2017; Jung et al., 2018; 
Tietze et al., 2020; Antonioli and Montresor, 2019). 
We show that decision makers can use patent infor-
mation and analytics to find data-driven innovation 
management solutions to overcome crisis situations, 
as in the COVID-19 pandemic. This includes the 
firm-internal view on own technologies and innova-
tion activities as well as the firm-external view on 
incumbent and novel competition and technology 
evolvement. Using cross-disciplinary insights from 
natural sciences and strategic patent management, we 
identify COVID-19 and related immunology-based’ 
patent families, detect key biotechnology firms 
already possessing experience in developing cures, 
treatment, and vaccination to related coronavirus dis-
eases using smart patent indicators and harmonized 
patent data. Moreover, we highlight why a promul-
gated U.S. interest in relocating firms like CureVac 
might not be without technological and commercial 
reasoning. Further, we demonstrate how firms like 
Adidas can optimize their budget constraints by 
detecting patent families that can be monetized, e.g., 
via sales or licensing deals, as well as potentially 
saving costs by focusing on impactful patent families 
and novel annuity fee measures. This provides firms 
with options to maintain innovative activities in crisis 
situations. Taken together, these case studies show 
how patent analytics support firms’ managements in 
mitigating crises like the COVID-19 pandemic and 
thus enabling them to emerge stronger eventually as 
a success story. Herein, we provide concrete recom-
mendations for management and depict arrays for 
future research.
2.  Theoretical background
2.1.  Innovation management in crises
Crises influence innovation management (Döner, 
2017; Teplykh, 2018; Antonioli and Montresor, in 
press). On the downside, prior research found crises 
to intensify ‘uncertainty, complexity, ambiguity and 
unpredictability’ (Davis et al., 2009; Martin-Rios 
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and Pasamar, 2018; Teplykh, 2018). Compared to 
favorable contexts, in which innovation thrives, inno-
vation is hindered in more unfavorable scenarios, 
creating innovation barriers, as in crises (Ferreira 
and Teixeira, 2016; Teplykh, 2018). For example in 
the financial crises of the late 2000’, firms changed 
their innovation behavior (Cruz-Castro et al., 2018). 
Disoska et al. (2020) found an indication that crises 
have a negative influence on firms’ willingness to 
innovate. Some firms only maintain their innova-
tion activities in exchange for public support, which 
implies a de-facto reduction in proprietary innova-
tion efforts (Antonioli and Montresor, in press). 
Decreases in firms’ revenues directly affect research 
and development, hence innovation outputs (Döner, 
2017).
On the upside, crises do not only entail adverse 
effects, but offer opportunities stimulating innovation 
(Carmeli and Schaubroeck, 2008; Ulmer et al., 2011; 
Cefis and Marsili, 2019; Heyden et al., 2020). When 
firms manage to meet the shifting market require-
ment and crises-induced necessities, they can emerge 
even stronger from these situations (Archibugi et al., 
2013a; Mayr et al., 2017). For example, Nemlioglu 
and Mallick (2020) interpret innovation as a path out 
of crisis-induced valuation uncertainty, where finan-
cially less-constrained, innovative firms yield higher 
values and experience less uncertainty. In the same 
vein, Heyden et al. (2020) identified that corporate 
management benefits from enabling radical change 
initiatives instead of cutting costs. Innovative activity 
may support firms in shielding themselves from cri-
ses’ effects, while other supposed resilience fostering 
actions, such as marginal production cost reductions, 
fail (Gupta, 2019). Cefis et al. (2020) found that 
innovations grant a survival premium. Regardless 
of firms’ financial conditions, innovative firms have 
higher probabilities than non-innovative firms to sur-
vive crises (Cefis et al., 2020).
2.2.  Innovation management and patent 
analytics
In addition to the link between crises and innova-
tion management, prior research has also established 
a relation between innovation management and 
patent analytics (Candelin-Palmqvist et al., 2012; 
Holgersson, 2013). To profit from innovation, firms 
often rely on intellectual property rights like pat-
ents to appropriate returns (Greenhalgh et al., 2001; 
Somaya, 2012; Di Minin and Faems, 2013; Bican 
et al., 2017). In industries like pharmaceuticals, this 
is particularly prevalent (Hemphill and Sampat, 
2012; Conley et al., 2013a; DiMasi et al., 2016). 
Patents are publicly available and serve as objective 
data sources on firms’ innovation activities (Ashton 
and Sen, 1988; Buehler et al., 2017; Guderian, 2019). 
Patents offer unique insights into technology and 
business activities of firms that could not be assessed 
by external parties otherwise (e.g., Ernst, 2003; Ernst 
and Omland, 2011). Patenting firms commonly rely 
on more than one patent, generating patent portfo-
lios with multiple patents in multiple jurisdictions 
through their inventive activities (Conley et al., 
2013b).
Measuring the impact of research and develop-
ment or innovation activities proves difficult (Bican 
and Brem, 2020). Commonly, innovation managers 
turn to patent analytics (e.g., Pavitt, 1985; Arundel 
and Kabla, 1998; Hall et al., 2005). For this purpose, 
various patent indicators have been applied, from 
patent portfolio sizes and patent citations toward 
data mined from patents and smart patent indicators 
(Allison et al., 2004; Buehler et al., 2017; Fankhauser 
et al. 2018; Guderian, 2019). This variety in patent 
indicators stems from the skewness of patent val-
ues and commercial applicability (e.g., Chesbrough 
et al., 2006; Gambardella et al., 2008; Webster and 
Jensen, 2011).
2.3.  Patent analytics in crises: the 
COVID-19 pandemic
Patents are cost-intensive over their entire lifetime, as 
filing and maintenance costs are due in each jurisdic-
tion where patent protection is sought (Duhigg and 
Lohr, 2012; Cho et al., 2018). Consequently, main-
taining existing or filing new patents is challenging 
when budgets are constrained, as in crisis situa-
tions (e.g., Archibugi et al., 2013a; De Rassenfosse 
and van Pottelsberghe de la Potterie, 2013; Hud 
and Hussinger, 2015). Here, cost-reduction is cru-
cial when it comes to patents, while simultaneously 
ensuring the continued protection of relevant inno-
vations and technologies (Helfgott, 1993; Harhoff 
et al., 2009). This ensures interpreting patents as stra-
tegic assets, which allow leveraging existing capabil-
ities and deploying promising business opportunities 
(Rivette and Kline, 2000; Di Minin and Faems, 2013; 
Bican et al. 2017). However, this strategic view of 
intellectual property is underrepresented in the extent 
literature on innovation management in crises: Only 
a few early attempts to link propositions to over-
come the crisis and intellectual property exist (e.g., 
Machuca-Martinez et al., 2020; Tietze et al., 2020). 
Although scholars have acknowledged that patent 
information can be used, among others, for techno-
logical forecasting, business planning, or strategic 
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R&D planning, the value and use of patent informa-
tion in crises have largely been overlooked, resulting 
in a knowledge gap (Campbell, 1983; Ashton and 
Sen, 1988; Ernst, 2003). By means of this research, 
we fill this void.
In the current COVID-19 pandemic, this 
approach implies an understanding of the biology 
of the peculiarities, root causes, and effects of the 
virus. Otherwise, strategies to cope with the pan-
demic become arbitrary, ad hoc, and rely on gut 
feelings (Müller, 1985; Cooper and Edgett, 2010; 
Bessant et al., 2015). In the case of the COVID-19 
virus, the human body reacts in the following man-
ner: Cytokines are the proteins released as immune 
response against infections, genetic disorder, or 
autoimmune diseases (Testar, 2020). They cause 
localized inflammation in the region of attack (Van 
Der Meide and Schellekens, 1996). However, in 
exceptional cases, there is an uncontrolled release 
of pro-inflammatory cytokines that ultimately 
cause the body’s own immune system to work 
against itself leading to multiple organ failures 
and even death (Wang and Ma, 2008). This unre-
strained expression of cytokines and other immune 
response cells and mediators leading to unchecked 
activation of the immune system is referred to as 
‘cytokine storm’ (Dance, 2020). Cytokine storm 
has been encountered in patients during the out-
break of SARS-CoV (Huang et al., 2005) and 
H5N1 influenza virus (Yuen and Wong, 2005). It 
is also associated with non-infectious diseases like 
graft-versus-host disease (Ferrara, 1993), multiple 
sclerosis (Link, 1998), pancreatitis, juvenile arthri-
tis (Goodman, 2020), lupus, and Still’s disease.
The COVID-19 virus triggers a similar response 
once it enters the lungs of the infected patients 
(Van Der Meide and Schellekens, 1996; Goodman, 
2020). When the immune response to this infec-
tion becomes uncontrolled it results in uninhibited 
production of cytokines that cause cell death at 
the tissue lining the walls of the lungs leading to 
pneumonia and oxygen shortage. This initiation of 
lung failure further leads to acute respiratory dis-
tress syndrome ARDS (Ye et al., 2020) and is fol-
lowed by the failure of other organs. Thus, drugs 
that act as immunosuppressants and thus block the 
immune cell mediators (cytokines) are being tested 
to treat the COVID-19 infection. The COVID-19 
infection causing SARS-Cov-2 virus belongs to the 
beta class of the family of coronaviruses termed 
Coronaviridae like the SARS-CoV and Middle 
East respiratory syndrome (MERS) virus (MERS-
CoV) (Liu et al., 2020). These are single-stranded 
RNA viruses with four kinds of structural pro-
teins (Sidedell et al., 2010; Aronson, 2020). The 
membranes of these viruses have glycoprotein 
spikes which are responsible for their ‘crown’ like 
or ‘corona’ like appearance under the microscope 
(ScienceDirect, 2020; Zhang, 2020). These spike 
proteins anchor the virus onto the host human cell; 
this process is the same in SARS-Cov, Mers-CoV, 
and SARS-Cov-2 viruses (Li et al., 2020). There 
is more than 70% similarity between the genetic 
sequence of SARS-Cov-2 virus and the SARS-CoV 
virus and more than 50% with MERS coronavirus 
(Park et al., 2020).
There is no known antidote against the SARS-
Cov-2 virus. In the current crisis, research in treat-
ment methods for COVID-19 infections is based on 
the knowledge that is available from the SARS and 
MERS epidemic in the past and treatment methods 
so far have been adopted from these past infectious 
respiratory disease epidemics (Park et al., 2020). 
One of the treatment methods under study is the 
development of antibodies that target the Spike 
protein of the virus (Liu et al., 2020). The other 
method that is pursued is the development of an 
mRNA vaccine that can trigger the body’s immune 




To address the identified gap in the literature, we 
chose an exploratory, qualitative multiple case study 
research approach (Yin, 2018). Due to the lack of 
prior empirical substantiation as well as the nature 
of our research question (‘how’), such qualitative 
research design was required (Eisenhardt, 1989; Yin, 
2018). We rely on four distinct situations of cases 
that are based on longitudinal and cross-sectional 
patent data (Yin, 2018); two of which address the 
downside and two the upside of crisis situations for 
innovation. We searched cases that address the down-
side to study how patent analytics can be used to cir-
cumvent budget constraints by discerning patents 
that can be monetized (Case 1: Adidas AG’s Patent 
Families) or abandoned to achieve cost-savings 
(Case 2: Adidas AG’s Annuity Fees), and cases that 
address the upside to investigate how patent analytics 
can be used to detect key biotechnology firms (Case 
3: CureVac’s Patent Portfolio) that are likely to suc-
cessfully develop treatments and vaccinations (Case 
4: COVID-19 Treatment and Vaccination) against 
COVID-19.
The respective cases were identified in the busi-
ness press related to the COVID-19 pandemic at the 
Innovation management in crisis
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height of the April 2020 lockdown in Europe. Adidas 
had been in the news for surprisingly obtaining a 
state-backed loan from the federal German bank KfW, 
while CureVac drew a prolonged relocation interest 
by U.S. authorities (e.g., Bennhold and Sanger, 2020; 
Erhardt, 2020). We obtained the corresponding data, 
including all measures, from the PatentSight Business 
Intelligence Analytics Software as of May 7, 2020. For 
the first two case studies, we queried information on 
the patent portfolio owned by Adidas AG, including 
its subsidiaries and subsidiaries’ subsidiaries, using 
the databases’ interface. The unit of analysis is the 
patent family, i.e., the ‘set of either patent applications 
or publications taken in multiple countries to protect 
a single invention by a common inventor(s) and then 
patented in more than one country’ (European Patent 
Office, 2017). The Adidas patent portfolio comprises 
a total of 875 patent families, of which 434 are active. 
The empirical unit for case study one is the patent 
family. The empirical unit for case study two is the 
annuity fees due per patent office and year.
For case study three, we queried information for 
the patent portfolio owned by CureVac AG, including 
its subsidiaries and subsidiaries’ subsidiaries, using 
the databases’ interface. The unit of analysis is the 
patent portfolio. The CureVac patent portfolio com-
prises a total of 123 patent families, of which 105 are 
active. The empirical unit for case study three is the 
patent portfolio strength (Ernst and Omland, 2011).
For case study four, we identified patent fami-
lies related to Coronaviridae viruses. For the patent 
searches, we use keyword combinations in patents’ 
titles and abstracts as well as Cooperative Patent 
Classification classes (Swiss Federal Institute of 
Intellectual Property, 2018; Guderian, 2019). The 
unit of analysis is the patent family. Cytokine storm 
treatment, COVID Spike protein treatment, COVID 
Spike protein vaccine, and COVID mRNA vac-
cine-related patent search yield totals of 9,494, 271, 
115, and 452 patent families, of which 3,059, 128, 
48, and 266 patent families are active for these indi-
vidual technologies on May 7, 2020, respectively. 
The empirical unit is the number of patent fami-
lies per owner and their average quality (Ernst and 
Omland, 2011).
3.2.  Analyses
Our analyses are conducted in the PatentSight 
Business Intelligence Analytics Software. For 
Adidas’ patent portfolio, we use the values of the 
Internal Technology Relevance on the abscissa and 
the External Technology Relevance on the ordinate 
(see Appendix for corresponding patent indicator 
definitions). Each patent family owned by Adidas is 
plotted according to its remaining lifetime values. For 
the second case study, we filter for all of Adidas’ pat-
ent families and the two subsamples derived in the 
first case study to detect the annuity fees. For the third 
case study, we filter for CureVac’s patent portfolio and 
display the Patent Asset Index for their technology 
clusters longitudinally from 2001 to 2019. Moreover, 
we also filter for the Patent Asset Index of other firms’ 
patent families that build on CureVac’s patent families 
as prior art. In addition, we collect data on protected 
authorities and inventor locations. For the fourth 
case study, we search for patent families concerning 
Coronaviridae viruses and related treatment methods. 
In light of the crisis, it is necessary to search for pat-
ent families and their owners that possess the required 
preliminary inventive know-how in this field. Our 
approach in patent searching is to identify these key 
players who have already performed the groundwork 
for the fight against the COVID-19 infection in terms 
of treatment methods such as for cytokine storm. The 
keywords related to the cytokine storm treatments are 
searched for in patents’ titles and abstracts. Diagnostic 
methods in this field are not being considered which 
means that the corresponding CPC class G01N has 
been excluded. This process ultimately reveals the 
patents that explicitly disclose inventions concerning 
treatment methods of cytokine storm. Searching for 
patents based on the inventions made after the SARS 
and MERS outbreak can provide the already available 
knowledge base regarding the ongoing approaches 
against the virus. The patent search is focused on the 
inventions in the treatment of SARS or MERS infec-
tion targeting the Spike or S protein or the mRNA 
vaccine. Each of the specific treatment options is 
investigated more closely by analyzing the patents 
related to each of the Spike protein-based methods 
and mRNA-based methods separately. The Spike 
protein-based keywords are searched in patents’ titles 
and abstracts, while the SARS- and MERS-related 
keywords are searched in patents’ titles, abstracts, and 
claims. A similar approach for mRNA vaccine-based 
patents is followed.
4.  Results
4.1.  Case 1: Adidas AG’s patent families
Figure 1 depicts the Adidas’ patent portfolio. The 
patent families are plotted according to their Internal 
Technology Relevance and External Technology 
Relevance values. The bubble sizes represent the 
remaining lifetimes. All 434 Adidas patent fami-
lies active on May 7, 2020, are spread out across 
the two axes. Most patent families are located close 
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to the origin, hence have low Internal and External 
Technology Relevance values. The average Internal 
Technology Relevance and External Technology 
Relevance is 0.79 and 2.92, respectively.
4.2.  Case 2: Adidas AG’s annuity fees
Figure 2 depicts the patent office annuity fees of 
Adidas’ patent portfolio due until the end of the 
patents’ lifetimes. While the first row depicts the 
entire portfolio, the second and third rows depict 
the annuity fees for the patents that may be aban-
doned and sold or licensed-out, as identified in the 
first case study. In total, Adidas has to pay approx-
imately USD 20 million in annuity fees to the 
respective patent offices like the USPTO and EPO 
(see Figure 2). For the abandonment candidates, 
Adidas has to pay about USD 7 million in annuity 
fees, while for the sale and licensing-out candidates, 
about USD 4 million have to be paid. The cost-sav-
ing potential of USD 11 million accounts for 55% of 
all annuity fees due.
Figure 1. Adidas’ patent portfolio: Internal- vs. external technology relevance. Source: PatentSight Business Intelligence Analytics 
Software, own export, May 7, 2020.
Figure 2. Adidas’ patent portfolio: Annuity fee payment in USD at various patent offices. Source: PatentSight Business Intelligence 
Analytics Software, own export, May 7, 2020.
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4.3.  Case 3: CureVac’s patent portfolio
Figure 3 depicts the Patent Asset Index of CureVac’s 
patent portfolio separated by the technology clus-
ter to which its patent families are classified using 
semantic rules of similarity (Hartmann, 2020; 
PatentSight GmbH, 2020). All 18 technology clus-
ters between the first patent family in 2001 and 
2019 (105 patent families) grew substantially, with 
a Patent Asset Index of 2,017 in 2019. For protein, 
the Patent Asset Index grew from 3 in 2009 to 442 in 
2019, while mRNA polymerase patent families had a 
Patent Asset Index of 3 in 2005 and 220 in 2019. All 
virus-related patent families showed a Patent Asset 
Index of 26 in 2019.
Figure 4 presents the Patent Asset Index of the pat-
ent families owned by other firms that cite CureVac’s 
patent families. This allows to identify closely 
related firms that build on CureVac’s patent families 
as prior art. Among the top 15 firms that build on 
CureVac’s patent portfolio with the strongest patent 
portfolio, we identified biotechnology firms such as 
Moderna Therapeutics and Acuitas Therapeutics, 
but also established pharmaceutical firms such as 
Roche, universities such as Harvard University and 
the University of Mainz as well as research institutes 
like the Ludwig Institute.
On a world map, Figure 5 highlights where 
CureVac’s patent families are active and Figure 6 
shows where the patent families have been invented 
Figure 3. CureVac: Patent Asset index by technology cluster (level 3) from 2000 to 2019. Source: PatentSight Business Intelligence 
Analytics Software, own export, May 7, 2020.
Figure 4. CureVac: Patent asset index for firms’ patents citing CureVac from 2007 to 2019. Source: PatentSight Business Intelligence 
Analytics Software, own export, May 7, 2020.
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based on inventor locations. CureVac’s patent fami-
lies originate in Germany, with few co-origin author-
ities (e.g., Switzerland, USA). In contrast, CureVac 
protects its patents across the globe, with the stron-
gest portfolios active in the United States.
4.4.  Case 4: COVID-19 treatment and 
vaccination – competitive landscape
Figure 7 depicts the top 15 patent owners of Cytokine 
storm treatment with their respective portfolio sizes, 
average Competitive Impacts, and Patent Asset Index 
values. Moreover, besides big pharma (e.g., Bristol-
Myers Squibb), small biotech firms (e.g., Ono 
Pharmaceutical) are active in Cytokine storm treat-
ment. Focusing on COVID Spike protein treatment, 
Figure 8 illustrates the filing activities on patents for 
this treatment. Incorporating active, inactive, and 
pending patents in green, red, and yellow color, the 
filing activities show peaks for 2003 to 2004 as well 
as 2013 to 2017, following the SARS and MERS out-
breaks, respectively.
The most prominent case is Gilead Sciences, 
whose Remdisivir is the frontrunner in the race 
toward the treatment of cytokine storm in covid-19 
infections (PMGroup, 2020). Aduro Biotech and Ono 
Pharmaceutical’s portfolios feature low numbers 
of patent families but high average qualities. These 
firms are known to possess drugs that target inflam-
matory and autoimmune diseases and have already 
been taken note of in the current pandemic scenario 
(Aduro Biotech, 2020; Liu et al., 2020). Regeneron 
has reported the trial test of its arthritis drug Kevzara 
to treat cytokine storm in COVID-19 patients 
Figure 5. CureVac: Protected authorities. Source: PatentSight Business Intelligence Analytics Software, own export, May 7, 2020.
Figure 6. CureVac: Inventor locations. Source: PatentSight Business Intelligence Analytics Software, own export, May 7, 2020.
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(Erman and Threlfall, 2020). Roche is also conduct-
ing tests on its arthritis drug ACTEMRA (DeArment, 
2020b; Liu and Miller, 2020) to treat COVID-19 
pneumonia, while Incyte has reported its plan for the 
trial of its blood cancer drug as a potential treatment 
for COVID-19 cytokine storm (DeArment, 2020a).
For the COVID Spike protein-based search, only 
48 active patent families with a Patent Asset Index 
of 86 are identified. Discerning them by owner 
type (Figure 9), 64% are owned by firms, 35% 
by research and governmental bodies, and 1% is 
co-owned. University of Oxford features among the 
top patent-owners and the retrieved patents include 
the one disclosing the specific adenovirus vec-
tor ChAdOx1 based on which the current vaccine 
the whole world is waiting for and which has been 
Figure 7. Cytokine storm treatment: Top 15 firms by the patent asset index. Source: PatentSight Business Intelligence Analytics Software, 
own export, May 7, 2020.
Figure 8. COVID-Spike protein treatment: Filing activities and patents’ legal statuses. Source: PatentSight Business Intelligence Analytics 
Software, own export, May 7, 2020.
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licensed to AstraZeneca, has been developed. In the 
mRNA-based vaccine-related patents, the two stron-
gest patent portfolios as per the bubble area that indi-
cates portfolio strength, are owned by CureVac and 
Moderna Therapeutics, where CureVac owns five 
and Moderna Therapeutics three patent families. The 
average Competitive Impact values are quite high, 
but portfolio sizes relatively low with single patent 
family for firms like Sanofi, while Emory University 
has six patent families with lower Competitive 
Impact (see Figure 10).
Latest news states that Moderna’s pioneer vaccine 
technique with its mRNA-1273 in treating COVID-19 
infection has got FDA approval to proceed to the sec-
ond phase of testing (Saplakoglu, 2020). This vaccine 
is based on the research Moderna was conducting 
for the MERS vaccine (Harbert, 2020). CureVac 
has received an 80 million grant from the European 
Union to develop an mRNA based COVID-19 vac-
cine (Bahrke and Grammenou, 2020).
5.  Discussion
Innovation management may rely on patent ana-
lytics to overcome crisis situations like the current 
COVID-19 pandemic based on data-driven instead of 
ad-hoc decisions. As shown in the case study one, 
patent analytics can be applied to identify patent 
families that can be abandoned, sold, or licensed-out. 
Using citation metrics, we show that patent families 
with below-average internal citations may be consid-
ered candidates. Looking at external citations from 
third-party patent portfolios and considering above- 
or below-average values may further support aban-
donment, sale, or licensing decisions.
Figure 9. COVID Spike protein vaccine: Owner types by patent asset index. Source: PatentSight Business Intelligence Analytics Software, 
own export, May 7, 2020.
Innovation management in crisis
R&D Management 2020 11© 2020 The Authors. R&D Management published by RADMA and John Wiley & Sons Ltd
Adding annuity fee considerations, as shown in 
case study two, provides the first indication of poten-
tial cost-saving opportunities. However, these annu-
ity fees cover patent office fees only. Consequently, 
associated legal fees for attorneys or patent enforce-
ment costs diminish. Proceedings from the sale of 
patent families or licensing fees improve the finan-
cial position further.
Patent analytics allow for a better understanding 
of firms’ strategies through their patent portfolios, as 
shown in case study three. For example, firms may 
identify where to seek protection, where to create 
R&D centers, where white spots exists, or where 
to find collaboration partners (e.g., Ernst, 2003; 
Somaya, 2012; Di Minin and Faems, 2013; Guderian, 
2019). Applying patent value indicators to detect 
firms with above-average patent portfolios related 
to Coronaviridae virus treatment and vaccination, 
allows for data-driven innovation management deci-
sions. For example, CureVac’s average Competitive 
Impact (at 18.1) as a measure of average patent qual-
ity is about 18 times higher than the average of all 
active patent families worldwide. Hence, local gov-
ernments’ inclinations to shield these firms from 
acquisition by foreign entities or relocation through 
foreign governments, become comprehensible. Also, 
in terms of the patents’ origins and the geographical 
scope of protection, we see stark differences.
Information mined from patents allows measur-
ing innovation output and future knowledge flows, as 
shown in case study four (Buehler et al., 2017; Ernst 
et al., 2020). The innovation-driven patent activity 
shows a rise after the SARS and the MERS outbreaks 
in the past. This brings forth the trend of increased 
innovative activity after pandemics. In addressing 
crisis situations, the conventional patent searching 
process where the field of search is kept broad needs 
to be substituted by more narrow, focused approaches 
to bring into light the information about those entities 
as in patent owners that explicitly disclose the R&D 
and invention in a particular area. Consequently, firms 
like Moderna and Curevac as well as institutions like 
the University of Oxford are identified. Innovations 
are lengthy processes and in their development, they 
leave behind footprints that can be identified through 
various methods, one of which is patent analytics.
5.1.  Theoretical implications
Prior research identified crises to impact innovation 
in firms (Döner, 2017; Teplykh, 2018; Antonioli 
and Montresor, in press). A frequent response to 
crisis-induced detriments is the reduction of inno-
vation activities to cope with issues such as bud-
get constraints (Döner, 2017; Cruz-Castro et al., 
2018). Simultaneously, some firms manage to use 
crises for their benefits to emerge even stronger 
(Archibugi et al., 2013a; Cefis and Marsili, 2019). 
While in normal (non-crisis) times innovation man-
agement decisions are often crafted and executed 
using data like patent indicators, patent analytics 
have so far been largely neglected in responding to 
the challenges for innovation management imposed 
by crises. As our key theoretical contribution, we 
discuss and establish the relation between cri-
ses and patents. Thus, as shown in Figure 11, we 
Figure 10. COVID mRNA: Top 20 firms by the patent asset index. Source: PatentSight Business Intelligence Analytics Software, own 
export, May 7, 2020.
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complement the two dyadic relations between (1) 
innovation management and crises and (2) innova-
tion management and patents that have been estab-
lished in prior research by transforming these into 
a triadic relation between innovation management, 
crises, and patents.
As visible in the findings from our four case 
studies, we address firms’ internal and external 
spheres. Patent analytics allow innovation manage-
ment to craft own or forecast third-parties’ prob-
able responses to crises by data instead of ad-hoc 
or gut-feeling decisions. Moreover, our case stud-
ies address multiple levels of analyses, spanning 
inventions/technologies, firms, and competitive 
behavior.
Herein, we expand on recent early attempts to link 
propositions to overcome the crisis and intellectual 
property (e.g., Machuca-Martinez et al., 2020; Tietze 
et al., 2020). The findings from the patent analytics 
presented above confirm Cefis and Marsili (2019) in 
that technological innovations might trigger firms’ 
survivals in crises: ‘R&D investment is shown to be 
a poor choice for general firms to survive; however, 
it is an effective strategy for firms that are innova-
tive and capable of producing intellectual properties 
during recessionary periods’ (Jung et al., 2018).
5.2.  Practical implications
The insights of these studies yield valuable implica-
tions for innovation decision makers as well. First, 
innovation management can realize cost-savings by 
identifying patent families that do not add substan-
tial value to own or third parties’ business strategies. 
This budget may be used to maintain innovation 
activities in crises’ toughened endowments or cir-
cumstances. Second, annuity fees show minimum 
prices or royalty payments that need to be achieved 
in sale or licensing negotiations to reach break-even. 
Third, assessing firms’ patent portfolios allows to 
detect technological and strategic fit between busi-
ness strategies, innovation capabilities, and patent 
portfolios. This becomes visible in CureVac’s patent 
portfolio, as almost all of its patent families originate 
in Germany, whereas broad patent protection has 
been sought for in many developed and developing 
countries such as the G-7 and BRIC nations. Fourth, 
patent information may reveal data-driven predic-
tions for firms that are likely to succeed in develop-
ing treatments and vaccinations.
5.3.  Limitations and future research
As the COVID-19 pandemic is ongoing the results 
presented can only constitute preliminary assess-
ments. Actual performance effects of management 
strategies and potential differences to non-data-driven 
decisions cannot be compared at this stage, requir-
ing additional review once the pandemic has passed. 
Moreover, it is currently impossible to complement 
patent data with corporate data or actual decision 
-making schemes from corporate representatives 
to identify firms’ internal reasonings. However, 
the data used for the case studies are derived from 
objective, harmonized, and publicly available infor-
mation. This opens arrays for future research, par-
ticularly related to innovation management in times 
of crises like the current COVID-19 pandemic via 
the use of data-driven strategies derived from pat-
ent analytics. First, as firms proceed to cope with 
budget constraints and budget cuts, studying patent 
families actually sold, licensed, or abandoned, and 
comparing their patent quality and strength metrics 
might provide additional insights into value-driven 
patent management (Wurzer et al., 2016; Weibel and 
Freytag, 2019). Particular focus may be set on assess-
ing quality differences for innovations generated 
in-house versus those externally acquired. Second, 
future research may move from qualitative analyses 
and case studies toward empirical analyses to study 
actual performance effects of patent data-driven 
decisions in crisis situations. A promising approach 
in this context may be to expand the existing models 
toward multilevel or hierarchical models to combine 
patent data on individual patents or patent portfo-
lios with financial, economic, or medical data (e.g., 
Raudenbush and Byrk, 2002; Tabachnik and Fidell, 
2018). Third, research may shift to longitudinal con-
siderations, which is already partly performed in the 
Figure 11. Triadic relation: Innovation management, crises, and 
patents. Source: Own illustration.
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case studies presented in this study. Looking at pat-
ent data trends and development patterns over time 
may yield additional insights into how firms over-
came the crisis, allowing to make derivations for 
future pandemics or similar situations to come (e.g., 
Grover, 1999). This could support the detection of 
firms’ development of Coronaviridae treatment and 
vaccination development to end the pandemic.
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APPENDIX 
Technology Relevance measures the number of forward ci-
tations patents receive from subsequent patents, corrected 
for three issues commonly impeding the usefulness of pat-
ent citations, namely patent ages, different citation propen-
sities in different technology fields, and different citation 
propensities amongst different patent offices (Ernst and 
Omland, 2011).
The two derivative patent indicators to this patent in-
dicator, i.e., Internal Technology Relevance and External 
Technology Relevance, are calculated in the same manner. 
However, for the Internal Technology Relevance, only 
citations that stem from patents belonging to the same 
owner are considered. In contrast, for the External Tech-
nology Relevance, only citations that stem from patents 
belonging to third-party patents, i.e., patents not owned 
by the same owner as the focal patent, are considered. 
Herein, it becomes possible to disentangle citations from 
the same portfolio of third-party citations while continu-
ing to account for the issues impeding general forward 
citations patents receive. Further, it requires the consider-
ation of ownership structures in defining complete patent 
portfolios as a prerequisite (e.g., Buehler et al., 2017; 
Guderian, 2019).
Referring to patents as territorial rights, the Market 
Coverage refers to the sum of the gross domestic product 
of all countries where member documents of a patent fam-
ily are protected or pending relative to the gross domestic 
product of the United States of America as the largest 
world economy (Ernst and Omland, 2011). Contrasting 
measures of patent family sizes that simply sum the num-
ber of countries, the Market Coverage allows to consider 
differences in market sizes of the geographical scope of 
protection (e.g., Harhoff et al., 2003; Ernst and Omland, 
2011; Fischer and Leidinger, 2014).
Competitive Impact refers to the product of patents’ 
Technology Relevance and Market Coverage values, 
thereby representing their business value (Ernst and Om-
land, 2011). Combining patents’ forward citations with 
the size of the markets where the patents are protected, 
allows an assessment of their quality; high-quality patents 
require both: impacts as prior art to subsequent patents as 
well as broad protection scopes given that patents are ter-
ritorial rights that can only be enforced in markets where 
the patents have been established. The portfolio size refers 
to the number of patent families selected in the filter que-
ry. In the first three case studies, this refers to the number 
of patent families owned by all the firms that are a part 
of the corporate trees of Adidas and CureVac, i.e., their 
respective parent entity, subsidiaries, and subsidiaries’ 
subsidiaries. For the fourth case study, this refers to the 
number of patent families identified using the Coronaviri-
dae virus searches, irrespective of their owners.
Patent Asset Index is the sum of the Competitive 
Impact values of all patents constituting portfolios such 
as the aforementioned portfolios of Adidas, CureVac, and 
Coronaviridae virus (Ernst and Omland, 2011). Conse-
quently, dividing the Patent Asset Index by the portfolio 
size for a selected patent portfolio yields the portfolio’s 
Average Competitive Impact, i.e., the average quality of 
the patents belonging to this portfolio as measured by the 
Competitive Impact.
